title: Variant prostate carcinoma and elevated serum CA-125.
abstract: BACKGROUND
  About 10% of tumors derived from nongynecologic, noncoelomic tissues react with the OC125 antibody. Some patients with advanced prostate cancer were found to have elevated serum CA-125 level.
  
  
  METHODS
  We examined the clinical history of 11 patients with castration resistant prostate cancer and an elevated serum CA-125 level. Pathological review and immunohistochemical staining were performed on tumors from eight of these patients.
  
  
  RESULTS
  Patients with advanced prostate cancer and an elevated serum CA-125 level responded to androgen ablative therapy (median duration, 27 months). They were predisposed to develop persistent or recurrent urinary symptoms and visceral metastases. Eight of 11 patients had a low or undetectable serum prostate-specific antigen level (≤ 4 ng/mL) or an elevated serum carcinoembryonic antigen level (> 6 ng/mL). In 3 of 7 patients whose specimens were available for further review, the tumors contained histologic features compatible with a diagnosis of ductal or endometrioid adenocarcinoma of the prostate.
  
  
  CONCLUSIONS
  Patients with prostate cancer and an elevated serum CA-125 level have unique clinical and pathologic characteristics. Some of these patients possess tumors compatible with a subtype of prostate cancer known as ductal adenocarcinoma. Additional studies need to be performed to elucidate the biologic basis of the various subtypes of prostate cancer.
authors.affiliation: The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors.forename: Mehmet Asim
authors.initials: MA
authors.lastname: Bilen
authors.forename: Adriana
authors.initials: A
authors.lastname: Reyes
authors.forename: Deb
authors.initials: D
authors.lastname: Bhowmick
authors.forename: April
authors.initials: A
authors.lastname: Maa
authors.forename: Robert
authors.initials: R
authors.lastname: Bast
authors.forename: Louis L
authors.initials: LL
authors.lastname: Pisters
authors.forename: Sue-Hwa
authors.initials: SH
authors.lastname: Lin
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Logothetis
authors.forename: Shi-Ming
authors.initials: SM
authors.lastname: Tu
mesh_terms: D000230:Adenocarcinoma / Q000097:blood* / Q000188:drug therapy / Q000556:secondary; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018394:CA-125 Antigen / Q000032:analysis / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D017430:Prostate-Specific Antigen / Q000032:analysis / Q000097:blood; D064129:Prostatic Neoplasms, Castration-Resistant / Q000097:blood* / Q000188:drug therapy / Q000473:pathology*; D015996:Survival Rate
chemical_list: D018394:CA-125 Antigen; D002272:Carcinoembryonic Antigen; D017430:Prostate-Specific Antigen